United States Pharmaceuticals and Healthcare Report Q1 2016

United States Pharmaceuticals and Healthcare Report Q1 2016

Includes 3 FREE quarterly updates

BMI View:

The US pharmaceutical market will continue to display robust growth over the medium term despite efforts from the public and private sectors to reduce drug spending. Many newly launched patented drugs that have clear efficacy and safety benefits are able to command premium prices from payers. This external validation provides buoyancy to the industry, which has been recently accused of price gouging.


Headline

Expenditure Projections


- Pharmaceuticals: USD309.9bn in 2014 to USD326.9bn in 2015; +5.5% growth. Historic market size revised downwards significantly since Q315 due to adoption of new data source.
- Healthcare: USD3,006.4bn in 2014 to USD3,121.0bn in 2015; +3.8% growth. Forecast unchanged since Q315.
BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (United States 2013-2019) . 7
SWOT . 10
Industry Forecast .. 12
Pharmaceutical Market Forecast . 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (United States 2011-2019) 14
Healthcare Market Forecast . 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2011-2019) . . 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2011-2019) . . 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (United States 2011-2019) . . 23
Patented Drug Market Forecast .. 24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (United States 2011-2019) 25
Generic Drug Market Forecast 26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (United States 2011-2019) . 28
OTC Medicine Market Forecast .. 29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (United States 2011-2019) . 31
Pharmaceutical Trade Forecast .. 32
Table: Pharmaceutical Trade Data And Forecasts (United States 2013-2019) 33
Industry Risk Reward Index 34
Americas Risk/Reward Index 34
United States Risk/Reward Index . 41
Rewards .. 41
Risks . 41
Regulatory Review 43
Intellectual Property Issues . 58
Pricing & Reimbursement Regime . 59
Late-2013 Government Shutdown .. 61
Market Overview 64
Healthcare Sector . 65
Table: Key Features Of The Affordable Care Act By Year 67
Table: Healthcare Resources (United States 2009-2014) . 70
Table: Healthcare Personnel (United States 2009-2014) . 70
Table: Healthcare Activity (United States 2009-2014) . 71
Clinical Trials 71
Epidemiology . 73
Competitive Landscape . 76
Research-Based Industry . 76
Table: Multinational Market Activity . 77
Pharmaceutical Distribution .. 78
Company Profile . 79
Amgen 79
AstraZeneca . 83
Eli Lilly . 87
GlaxoSmithKline . 90
Merck & Co .. 93
Pfizer . 97
Demographic Forecast 100
Table: Population Headline Indicators (United States 1990-2025) . . 101
Table: Key Population Ratios (United States 1990-2025) 101
Table: Urban/Rural Population & Life Expectancy (United States 1990-2025) . 102
Table: Population By Age Group (United States 1990-2025) . . 102
Table: Population By Age Group % (United States 1990-2025) . . 103
Glossary 105
Methodology .. 107
Pharmaceutical Expenditure Forecast Model .. 107
Healthcare Expenditure Forecast Model 107
Notes On Methodology .. 108
Risk/Reward Index Methodology . 109
Index Overview 110
Table: Pharmaceutical Risk/Reward Index Indicators 110
Indicator Weightings . 111
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.